Glenmark Pharmaceuticals Launches Methylene Blue Injection USP in United States Market
Glenmark Pharmaceuticals Inc., USA has announced the launch of Methylene Blue Injection USP, 50 mg/10 mL (5 mg/mL) Single-Dose Vial. The launch marks a step in strengthening the company's institutional portfolio within the U.S. market.The new product is bioequivalent and therapeutically equivalent to ProvayBlue® Injection, 50 mg/10 mL (5 mg/mL), which is manufactured by Provepharm SAS [NDA 204630].
According to IQVIA® sales data for the 12-month period ending April 2026, the market for ProvayBlue® Injection, 50 mg/10 mL (5 mg/mL) recorded annual sales of approximately $19.0 million.
The key operational and market details are summarized below:
| Metric | Details |
|---|---|
| Product Launched | Methylene Blue Injection USP, 50 mg/10 mL (5 mg/mL) Single-Dose Vial |
| Equivalence Status | Bioequivalent and therapeutically equivalent to ProvayBlue® Injection |
| Reference Drug | ProvayBlue® Injection (Provepharm SAS) |
| Market Size (QLQ) | Approximately $19.0 million (for the 12-month period ending April 2026) |
Commenting on this significant launch, Marc Kikuchi, President and Business Head of North America at Glenmark Pharmaceuticals Inc., stated that the introduction of Methylene Blue Injection USP reflects the company's commitment to expanding access to quality and affordable medicines. He added that the addition further reinforces the focus on delivering reliable treatment options across the U.S. market.
GLENMARK Stock Price Movement
Glenmark Pharmaceuticals Limited edged higher on Tuesday, achieving a marginal gain of 0.06% and settling at ₹2156.70. The stock saw movement within a tight intraday range, dipping to a low of ₹2133 while trading volume registered 325,200 shares before the close.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.